Vericel Corp (VCEL)
NASDAQ:VCEL
VCEL Stock Chart & Stats
$33.70
$1.36(2.35%)
At close: 4:00 PM EST
$33.70
$1.36(2.35%)
Day’s Range― - ―
52-Week Range$28.95 - $45.97
Previous CloseN/A
Volume83.17K
Average Volume (3M)699.99K
Market Cap
$1.72B
Enterprise Value$1.71B
Total Cash (Recent Filing)$137.50M
Total Debt (Recent Filing)$98.27M
Price to Earnings (P/E)110.3
Beta1.08
Next Earnings
May 13, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding50,931,600
10 Day Avg. Volume708,420
30 Day Avg. Volume699,990
Financial Highlights & Ratios
PEG Ratio1.93
Price to Book (P/B)5.14
Price to Sales (P/S)6.59
P/FCF Ratio73.61
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue6.21
Enterprise Value/Gross Profit8.34
Enterprise Value/Ebitda57.67
Forecast
1Y Price Target
$57.40Price Target Upside70.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.43
Revenue Forecast (FY)$322.56M
Bulls Say, Bears Say
Bulls Say
Commercial Expansion And Surgeon AdoptionCompleted expansion of the MACI sales force and a growing number of trained surgeons is increasing biopsy and implant activity, deepening product penetration and supporting sustained top-line growth.
Government ContractLong-term federal procurement agreement for NexoBrid secures recurring procurement revenue, offsets development costs, and could fund a room-temperature formulation and U.S. manufacturing to strengthen profitability and pipeline advancement.
Profitability And Cash FlowRecord revenue combined with stronger gross margins has driven renewed GAAP net income profitability and improved cash generation, reducing financial risk and enabling reinvestment in growth initiatives.
Bears Say
Commercial Ramp ExecutionSlower-than-expected commercialization at individual burn centers has delayed full revenue realization from the burn care franchise and creates dependency on additional catalysts to restore momentum.
Margin Pressure From InvestmentsHigher costs related to a new manufacturing facility, expanded sales headcount, and clinical programs are pressuring adjusted EBITDA margins and could constrain near-term profitability expansion.
Valuation RiskAnalyst neutral rating reflects that the stock trades at a premium to peers, limiting upside unless growth and profitability accelerate beyond current expectations.
Vericel News
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $28.95 and its highest was $45.97 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $1.72B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is May 13, 2026 which is in 32 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Feb 26, 2026. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.391 by $0.059.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is -0.15.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 50,931,600 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of $0.45 in its last earnings report, beating expectations of $0.391. Following the earnings report the stock price went up 1.591%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in VCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.40 (70.33% Upside)
$57.40 (70.33% Upside)
Blogger Sentiment
Neutral
VCEL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 42.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.07%
12-Months-Change
Fundamentals
Return on Equity
5.17%
Trailing 12-Months
Asset Growth
12.77%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and financial picture: record Q4 and full-year revenue, robust MACI momentum, substantial margin expansion, a strong cash position, successful sales‑force expansion, and advancement of clinical and manufacturing initiatives. Management provided constructive but conservative 2026 guidance that leaves room for upside from rep productivity, MACI Arthro adoption, and a potential BARDA award. Key risks include near-term margin compression (Q1), execution and ramp timing for the expanded sales force, reliance in part on pricing, and uncertainty around BARDA/NexoBrid timing. Taken together, the positive achievements (record growth, high margins, cash, product and clinical progress) noticeably outweigh the manageable near-term headwinds and uncertainties.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$57.40
▲(70.33% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---